ArticleTranslational oncology2026
SELE is associated with reduced breast cancer susceptibility: Evidence from Mendelian randomization and single-cell transcriptome.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe role of circulating proteins in breast cancer (BC) early diagnosis remains unclear. We investigated genetically predicted associations between circulating proteins and BC risk using Mendelian randomization (MR). This study aims to identify novel protein biomarkers through an integrative multi-omics approach.
methodsUsing a two-sample MR framework, we assessed genetically determined circulating protein associations with BC risk/subtypes. Analysis incorporated large-scale protein quantitative trait loci (pQTL) and genome-wide association studies (GWAS) data, strengthened by cross-validation, sensitivity analyses (MR-Egger, MR-PRESSO), and meta-analysis. We further performed genetic colocalization, molecular docking, and phenome-wide MR (PheWAS-MR). Bulk and single-cell RNA sequencing data were analyzed to compare gene expression of causal proteins between healthy and BC tissues. This multi-layered validation enhances the robustness of causal inference.
resultsThree circulating proteins are associated with reduced BC risk-SELE (OR = 0.98, 95 % CI: 0.97-0.98), CDH1 (OR = 0.94, 95 % CI: 0.93-0.95), ALPI (OR = 0.95, 95 % CI: 0.94-0.96). CNTNAP2 is associated with elevated BC risk (OR = 1.02, 95 % CI: 1.01-1.03). Colocalization supported shared causal variants for SELE and ALPI. Molecular docking simulation indicates high binding affinity of SELE-simvastatin. SELE expression was significantly reduced in endothelial cells of BC tissue, and PheWAS-MR revealed SELE's association with 123 phenotypes, highlighting its extensive pleiotropic effects.
conclusionsThis study provides robust genetic evidence for the causal roles of SELE, CDH1, and ALPI in reducing BC risk. The integrative proteomic-genetic-transcriptomic approach identifies potential therapeutic targets and offers new insights into BC pathogenesis, presenting hypotheses for clinical validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.